Drugs From Sponsors ‘Located in Russia,’ Would Be Barred From US FDA Review By House Funding Bill

 
• By Sarah Karlin-Smith
  
US, Russia, Ukraine, chess pieces
Congressional appropriators take aim at Russian pharma business in FY 2023 FDA funding • Source: Shutterstock

More from United States

More from North America